English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Oxprenolol (O) or propranolol (P) was randomly added double-blind to the regimen of 260 patients with mild and moderate hypertension who had not responded to hydrochlorothiazide (H) alone. Both beta-adrenergic blocking agents were titrated over a range of 120 to 360 mg per day while H was continued. After 6 months of treatment, reduction of diastolic blood pressure (DBP) to below 90 mm Hg and at least 5 mm Hg less than the initial DBP was achieved in 50% of patients receiving P+H and 27% of patients taking O+H (p less than 0.001). P+H lowered BP an additional 10.5/9.8 mm Hg compared with 6.8/7.0 mm Hg for O+H (p less than 0.02). Reduction in heart rate was less after O+H (average, 8.4/min) than after P+H (average, 12.3/min, p less than 0.01). The number of dropouts, morbid events, and reported side effects between the two regimens was not significantly different except that more patients complained of impotence with P+H than with O+H (p less than 0.05).

hypertension

Oxprenolol vs propranolol: a randomized, double-blind, multiclinic trial in hypertensive patients taking hydrochlorothiazide. Veterans Administration Cooperative Study Group.